Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Polymer Destroys Eosinophils and Reduces the Inflammatory Response

By LabMedica International staff writers
Posted on 08 Dec 2009
Allergy specialists have found that a synthetic polysaccharide could mimic the action of a monoclonal antibody and bind to an eosinophil surface lectin (sugar binding protein) in a fashion that triggered death of the cells with a subsequent reduction in overall immune inflammatory activity.

The lectin Siglec-8 (sialic acid-binding, immunoglobulin-like lectin), which is selectively expressed on eosinophil surfaces and regulates eosinophil survival, preferentially binds to the glycan 6′-sulfo-sialyl Lewis X (6′-sulfo-sLe X). More...
Sialyl Lewis X, also known as sialyl Le X and SLe X, is a tetrasaccharide carbohydrate that is usually attached to O-glycans on the surface of certain granulocytes and is known to play a vital role in cell-cell recognition processes. Sialyl Lewis X is one of the most important blood group antigens and is displayed on the terminus of glycolipids that are present on the cell-surface.
Investigators at Johns Hopkins University (Baltimore, MD, USA) prepared a soluble synthetic polymer displaying 6′-sulfo-sLe X glycan. They found that this polymer selectively bound to human eosinophils and human embryonic kidney 293 cells expressing Siglec-8. Binding was inhibited by anti-Siglec-8 antibody. In whole blood, eosinophils were the only leukocyte subtype to bind the polymer.

Further results published in the August 2009 issue of the Journal of Pharmacology and Experimental Therapeutics revealed that when working with pure cultures of eosinophils, the polymer killed about 65% of the eosinophils in about 72 hours. It was, however, not as effective as a specific monoclonal antibody, which killed up to 90% of the cells in 24 hours.

"This is initial proof that delivering the sugar through a polymer can give you the desired result of selectively engaging Siglec-8 and killing eosinophils, but we still have a long way to go,” said senior author Dr. Bruce S. Bochner, professor of allergy and clinical immunology at Johns Hopkins University. "The trick is that you need to engage several clusters of Siglec-8 on each cell at once to trigger cell death. You are not going to be able to do that with individual sugar molecules in solution.”

Related Links:

Johns Hopkins University



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.